Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

High-Risk de Novo Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Teclistamab
DRUG: Talquetamab

Sponsor

PETHEMA Foundation

Collaborators

[object Object]